The ICCS Quality and Standards committee has been working hard in order to make several more modules available on the ICCS website. We have had positive feedback from our first module on "
Lysing Methods and Reagents for Flow cytometric Immunophenotyping" which was posted last month on the ICCC website. Modules currently under review i
nclude “Identifying appropriate reagents to assess CD5 expression” and “Instrument Optimization for BC and BD platforms” which should be posted soon. “Reporting of CD5+ Neoplasms” and “Development of performance criteria for antibodies and guide for titration” are next in line.
It has been exciting to develop a focus and project ideas by this international group represented well between ICCS and ESCCA members who all bring various levels of expertise and experience to the group. One of the well-known ESCCA members Andy Rawstron has been actively involved in standardization projects for CLL and MRD testing for a long time and is now looking towards expanding this model into other areas, such as CMML, T-cell malignancies and hairy cell leukemia based on recent surveys. The goal is to include clinicians in order to identify the information needed for optimal patient management and subsequently develop consensus on assay-specific instrumentation setup, reagents, panels and reporting.
The Q&S committee is comprised of 4 groups (instrument optimization, reagents and panels, specimen preparation and reporting) which will address the most common areas of variability in flow cytometry. The information will be presented in peer-reviewed “modules” with the goal to provide the laboratory staff with a practical reference guide in optimizing their procedures.
Thank you for your participation in the ERIC/ESCCA/ICCS survey "p
rospective validation of flow cytometry panels for CLL diagnosis and monitoring". The results are now available, please click here to view them.
|